Andover, Massachusetts, United States
NCT Number: NCT02121847
Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy
This study will evaluate the safety and efficacy of cyclosporine 0.05% ophthalmic emulsion (Restasis®) in patients with dry eye disease.
Looking for future studies?
Notify MeKey information
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- History of dry eye in both eyes
- Willing to use eye drops for dry eye symptoms
Exclusion criteria
- Anticipate wearing contact lenses during the study
- Laser-assisted in situ keratomileusis (LASIK) surgery within the past 12 months
- Any ocular and/or lid surgeries within the past 6 months
- Cataract surgery in either eye
- Current or anticipated use of temporary punctal plugs during the study
Treatment and study plan
Cyclosporine 0.05% Ophthalmic Emulsion
DrugCyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.
Other names: Restasis®
carboxymethylcellulose-based lubricant eye drops
DrugCarboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
Other names: Refresh OPTIVE® Advanced
Primary outcomes
-
Change From Baseline in Total Corneal Staining Score With Fluorescein in the Worse Eye
Time frame: Baseline, Month 6
Total corneal staining with fluorescein is measured in the worse eye utilizing the Ora CalibraTM Corneal Flourescein Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).
-
Change From Baseline in Total Conjunctival Staining Score With Fluorescein in the Worse Eye
Time frame: Baseline, Month 6
Total conjunctival staining with fluorescein is measured in the worse eye utilizing the Ora CalibraTM Conjunctiva Flourescein Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).
-
Change From Baseline in Total Corneal Staining Score With Lissamine Green in the Worse Eye
Time frame: Baseline, Month 6
Total corneal staining with lissamine green is measured in the worse eye utilizing the Ora CalibraTM Corneal Lissamine Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).
-
Change From Baseline in Total Conjunctival Staining Score With Lissamine Green in the Worse Eye
Time frame: Baseline, Month 6
Total conjunctival staining with lissamine is measured in the worse eye utilizing the Ora CalibraTM Conjunctiva Lissamine Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).
-
Change From Baseline in Reading on the Ocular Surface Disease Index (OSDI)
Time frame: Baseline, Month 6
The OSDI consists of 12 questions measuring the presence of ocular symptoms. The reading question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The reading score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
-
Change From Baseline in Driving at Night on the OSDI
Time frame: Baseline, Month 6
The OSDI consists of 12 questions measuring the presence of ocular symptoms. The driving at night question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The driving at night score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
-
Change From Baseline in Working With a Computer or Bank Machine on the OSDI
Time frame: Baseline, Month 6
The OSDI consists of 12 questions measuring the presence of ocular symptoms. The working with a computer or bank machine question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The working with a computer or bank machine score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
-
Change From Baseline in Watching TV on the OSDI
Time frame: Baseline, Month 6
The OSDI consists of 12 questions measuring the presence of ocular symptoms. The watching TV question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The watching TV score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
-
Change From Baseline in Reading Rate
Time frame: Baseline, Month 6
Reading speed is assessed as the number of words read correctly in 2 minutes.
-
Change From Baseline in Words Read Incorrectly
Time frame: Baseline, Month 6
The numbers of words read incorrectly are counted in 2 minutes. A positive change from baseline indicates a worsening, and a negative change from baseline indicates an improvement.
-
Change From Baseline in Font Size
Time frame: Baseline, Month 6
The minimum font (letter) size read correctly is assessed. Smaller font size indicates better ability. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
Secondary outcomes
-
Change From Baseline in OSDI
Time frame: Baseline, Month 6
The OSDI consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions is assessed using a 5-point scale (0=none of the time; 4=all of the time). The score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
-
Change From Baseline in Ocular Discomfort on a 4-point Scale
Time frame: Baseline, Month 6
Ocular discomfort is assessed on a 4-point scale where 0=no discomfort and 3=most discomfort. A positive number change from baseline indicates a worsening and a negative number change from baseline indicates an improvement.
-
Change From Baseline in Tear Film Break-up Time in the Worse Eye
Time frame: Baseline, Month 6
TFBUT is defined as the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A positive number change from baseline indicates improvement and a negative number change from baseline indicates a worsening.
-
Change From Baseline in the Interblink Interval in the Worse Eye
Time frame: Baseline, Month 6
The interblink interval measures the time (seconds) between blinks in the worse eye. A positive number change from baseline indicates a worsening (more frequent blinks) and a negative number change from baseline (less frequent blinks) indicates an improvement.
-
Change From Baseline in Conjunctival Redness in the Worse Eye
Time frame: Baseline, Month 6
Conjunctival redness is scored in the worse eye on a numeric analog scale ranging from 0=None to 4=Extremely Severe (0.5 increments were allowed). A positive number change from baseline indicates a worsening and a negative number change from baseline indicates an improvement.
Sponsors and collaborators
Lead sponsor
Allergan
Industry
Registry information
Acronym: IMPACT
Important dates
- Study start
- 2014
- Primary completion
- 2014
- Study completion
- 2014
- First posted
- Apr 24, 2014
- Registry last updated
- Apr 18, 2019
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Efficacy and Safety Safety of Nutritears® in Adults With Dry Eye Syndrome
NCT05481450
Dry Eye, Dry Eye Syndromes
Lutz, Florida, United States
View Trial DetailsPreoperative iLux on Cataract Surgery Derived Dry Eye Disease Due to Meibomian Gland Dysfunction
NCT06483750
Cataract Senile, Dry Eye Disease
Washington D.C., District of Columbia, United States
View Trial DetailsTolerability Comparison of Flarex to Lotemax SM
NCT07588074
Conjunctival Diseases, Conjunctivitis
Baton Rouge, Louisiana, United States
View Trial DetailsAssessing the Impact of Tixel Treatment of Periorbital Wrinkles on Dry Eye Symptoms and Signs
NCT04730336
Dry Eye, Dry Eye Syndromes
Solihull, United Kingdom
View Trial Details